Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652686 | 0.84 | ALDH1A1 (0.35) | MAPTTSHRNPSR1 | |
| SCHEMBL7652396 | 0.81 | KIF11 (0.31) | — | |
| SCHEMBL7650392 | 0.77 | TSHR (0.39) | CNR2LMNATSHRNPSR1 | |
| SCHEMBL6935736 | 0.75 | CNR2 (0.37) | CNR2CNR1ABCC9ABCC8KCNJ11 | |
| SCHEMBL7650719 | 0.73 | CA9 (0.44) | MAPT | |
| SCHEMBL6935413 | 0.71 | CA9 (0.43) | MAPT | |
| SCHEMBL7651833 | 0.71 | KDM4E (0.35) | CNR2CNR1ABCC9ABCC8KCNJ11 | |
| SCHEMBL7652258 | 0.70 | ALDH1A1 (0.43) | MAPTTSHR | |
| SCHEMBL6939713 | 0.68 | POLB (0.36) | LMNATSHRNPSR1 | |
| SCHEMBL7652709 | 0.68 | KDM4E (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | CA6, P2RY6, FPR3 | CNR2 238/4885CNR1 160/4885PER2 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.